Preview

Психиатрия

Расширенный поиск

Применение ницерголина в геронтологической практике

Полный текст:

Аннотация

Цель работы - провести анализ литературных данных о применении ницерголина в лечении деменции.Материал и методы. В основу обзора литературы положена оценка эффективности и безопасности применения ницерголина при лечении деменции. Проведен анализ клинических особенностей деменции, также проанализированы современные подходы к медикаментозной коррекции этих расстройств. Описаны спектр биохимической активности и механизм действия ницерголина. Обсуждаются профиль и специфичность действия ницерголина и возможность сочетания его с другими лекарственными средствами по результатам преклинических и клинических исследований препарата.Вывод. Анализ данных многочисленных преклинических и клинических исследований свидетельствует о высокой эффективности и широком спектре действия ницерголина.

Об авторе

Елена Валерьевна Пономарева
ФГБНУ «Научный центр психического здоровья»
Россия


Список литературы

1. O’Connor D.W. Epidemiology / A. Burns et al. Dementia. 3nd ed. New York: Holder Arnold; 2005:16-23. DOI: 10.1201/b13239-4

2. Калын Я.Б., Гаврилова С.И. Динамика показателей распространенности психических расстройств в населении пожилого и старческого возраста (по данным клинико-эпидемиологических исследования населения старших возрастов на ограниченной территории Москвы. Международная конференция «Реформа службы психического здоровья: проблемы и перспективы»; Октябрь 21-22; Москва. 1997:181-189

3. Selkoe D.J. Aging Brain, Aging Mind. Sci. Am. 1992;267:134- 142. DOI: 10.1038/scientificamerican0992-134

4. Гаврилова С.И., Калын Я.Б. Социальные факторы и психические расстройства в пожилом и старческом возрасте // В кн.: Руководство по социальной психиатрии. Под ред. Т.Б. Дмитриевой. М. «Медицина»; 2001:136-161

5. Boiler F., Lopez O.L., Moossy J. Diagnosis of dementia: clin- icopathologic correlations. Neurology. 1989;39(1):76. http://dx.DOI.org/10.1212/WNL.39.1.76

6. Kalaria R.N., Ballard C. Overlap between pathology of Alzheimer’s disease and vascular dementia. Alzheimer dis- ease and Associated disorders. 1999;13(3):115-123. DOI: 10.1097/00002093-199912003-00017

7. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 2004;292(23):2901-2908. DOI: 10.1001/jama.292.23.2901

8. Руководство по гериатрической психиатрии. Под ред. С.И. Гавриловой. М.: Пульс. 2011:113-129

9. Михайлова Н.М. Диагностика и терапия смешанной (альцгеймеровско-сосудистой) деменции. Современная терапия в психиатрии и неврологии. 2012;3:18-26

10. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in commu- nity-dwelling older persons. Neurology. 2007;69:2197-2204. DOI: http://dx.DOI.org/10.1212/01. wnl.0000271090.28148.24

11. Левин О.С. Диагностика и лечение деменции в клинической практике. М. «Медпресс-информ»; 2010:255

12. Aguero-Torres H., Kivipelto M., von Strauss E. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen Project. Dement. Geriatr. Cogn. Disord. 2006;22 (3):244-249. DOI: 10.1159/000094973

13. Girouard H., Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 2006;100(1):328-335. DOI: 10.1152/japplphysiol.00966.2005

14. Roman G.C., Kalaria R.N. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol. Aging. 2006;27 (12):1769-1785. DOI: http://dx.DOI.org/10.1016/j.neurobiolaging.2005.10.004

15. Rockenstein E., Mallory M., Mante M. et al. Effects of Cerebrolysin in Human APP Transgenic Animal Modelsof Alzheimer’s disease. Neurobiol. Aging. 2000;21:168. DOI: http://dx.DOI.org/10.1016/S0197-4580(00)82095-3

16. Winblad B., Fioravanti M., Dolezal T. et al. Therapeutic Use of Nicergoline. Clinical Drug Investigation. 2008;28(9):533- 552. DOI: 10.2165/00044011-200828090-00001

17. Winblad B., Carfagna N., Bonura L. et al. Nicergoline in dementia: a review of its pharmacological properties and therapeutic potential. CNS Drugs. 2000; 14 (4):267-287. DOI: 10.2165/00044011-200828090-00001

18. Arcari G., Dorigotli L., Fregnan G.B. et al. Vasodilating and alpha-receptor blocking activity of a new ergoline deriva- tive. Br. J. Pharmacol. 1968;34(3):700

19. Alvarez-Guerra M., Bertholom N., Garay R.P. Selective block- ade by nicergoline of vascular responses elicited by stimu- lation of alphaiA-adrenoceptor subtype in the rat. Fundam. Clin. Pharmacol. 1999;13(1):50-58. DOI: 10.1111/j.1472-8206.1999.tb00320.x

20. Mirzoyan R.S., Ganshina T.S., Pukhalskaya T.G. et al. Effects of nicergoline in experimental models related to pathogenesis of migraine. Methods Find. Exp. Clin. Pharmacol. 1989;11(11):671-676

21. Le Poncin-Lafitte M., Grosdemouge C., Duterte D. et al. Simul- taneous study of haemodynamic, metabolic and behavioural sequelae in a model of cerebral ischaemia in aged rats: ef- fects of nicergoline. Gerontology. 1984;30(2):109-119. DOI: 10.1159/000212616

22. Pogliani E., Delia Volpe A., Ferrari R. et al. Inhibition of human platelet aggregation by oral administration of nicergoline: a double-blind study. Farmaco. Lprat. J. 1975;30(12):630-640

23. Moretti A., Carfagna N., Caccia C. et al. Effect of ergolines on neurotransmitter systems in the rat brain. Arch. Int. Pharmacodyn. Ther. 1988;294:33-45

24. Carfagna N., Rossi A. Nicergoline: biochemical studies on neuronal metabolism. Funct. Neurol. 1989;4(4):177-185

25. McArthur R.A., Carfagna N., Banfi L. et al. Effects of nicergo- line on age-related decrements in radial maze performance and acetylcholinelevels. Brain Res. Bull. 1997;43(3):305-311. DOI: 10.1016/S0361-9230(97)00010-5

26. Carfagna N., Di Clemente A., Cavanus S. et al. Modulation of hippocampal ACh release by chronic nicergoline treat- ment in freely moving young and aged rats. Neurosci. Lett. 1995;197(3):195-198. DOI: 10.1016/0304-3940(95)11928-P

27. Ogawa N., Asanuma M., Hirata H. et al. Cholinergic defi- cits in aged rat brain are corrected with nicergoline. Arch. Gerontol. Geriatr. 1993;16(2):103-110. DOI: http://dx.DOI.org/10.1016/0167-4943(93)90001-X

28. Carfagna N., Cavanus S., Damiani D. el al. Modulation of phosphoinositide turnover by chronic nicergoline in rat brain. Neurosci. Lett. 1996;209(3):189-192. DOI: 10.1016/0304-3940(96)12634-3

29. Caputi A., Di Luca M., Pastorino L. et al. Nicergoline and its metabolite induce translocation of PKC isoforms in selective rat brain areas. Neurosci. Res. Commun. 1998;23(3):159-167. DOI: 10.1002/(sici)1520-6769(199811/12)23:3<159::aidnrc4>3.0.co;2-

30. Cattabeni F. Protein kinase С in synaptic plasticity: a mo- lecular target in the treatment of cognitive disorders. De- ment. Geriatr. Cogn. Disord. 1997;8(1):6-11. DOI:10.1159/000106665

31. Checler F. Processing of the β-amyloid precursor protein and its regulation in Alzheimer’s disease. J. Neurochem. 1995;65(4):1431-1444. DOI: 10.1046/j.1471-4159.1995.65041431.x

32. Miccheli A., Puccetti C., Capuani G. et al. GIucose entry in neuronal and astrocytic intermediary metabolism of aged rats: a study of the effects of nicergoline treatment by 13C NMR spectroscopy. Brain Res. 2003;966(1):116-125. DOI:10.1016/S0006-8993(02)04217-8

33. Nishio T., Sunohara N., Furukawa S. et al. Repeated injec- tions of nicergoline increase the nerve growth factorlevel in the aged rat brain. Jpn. J. Pharmacol. 1998;76(3):321-323. DOI: http://DOI.org/10.1254/jjp.76.321

34. Giardino L., Giuliani A., Battaglia A. et al. Neuroprotec- tion and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion®). Neuroscience. 2002;109(3):487-497. DOI: http://dx.DOI.org/10.1016/S0306-4522(01)00470-5

35. Sortino M.A., Battaglia A., Pamparana F. et al. Neuroprotec- tive effects of nicergoline in immortalized neurons. Eur. J. Pharmacol. 1999;368(2-3):285-290. DOI: 10.1016/S0014-2999(99)00041-2

36. Caraci F., Chisari M., Frasca G. et al. Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against (β-amyloid toxicity). Brain Res. 2005;1047(1):30-37. DOI: http://dx.DOI.org/10.1016/j.brainres.2005.04.004

37. Tanaka M., Yoshida T., Sotomatsu A. et al. Inhibitory effect of nicergoline on production of active oxygen species by neutrophils and autooxidation of brain tissue [abstract]. Rinsho. Shinkeigaku. 1997;37(12):1229

38. Tanaka M., Yoshida T., Okamoto K. Inhibitory effect of nicer- goline on superoxide (O2O production by cultured microg- lia (MG) [abstract]. Rinsho. Shinkeigaku. 1999;39(1):299

39. Voronina Т.А., Nerobkova L.N., Garibova T.L. et al. Effect of nicergoline onlearning and memory. Methods Find. Exp. Clin. Pharmacol. 1988;10(7):431-435

40. Schindler U., Rush D.K., Fielding S. Nootropic drugs: animal models for studying effects on cognition. Drug Dev. Res. 1984;4:567-576. DOI: 10.1002/ddr.430040510

41. Lograno M.D., Tricarico D., Masciopinto V. et al. Specific binding of nicergoline on an α1-like adrenoreceptor in the rat retina. J. Pharm. Pharmacol. 2000;52(2):207-211. DOI: 10.1211/0022357001773706

42. Protti R., Cipullo D., Boles Carenini A. et al. Evaluation of the efficacy of nicergoline on blood flow and ocular func- tion in patients affected by chronic simple glaucoma. Acta Ophthalmol. Scand. 1998;227:42-45. DOI: 10.1111/j.1600-0420.1998.tb00881.x

43. Blasco G., Traversa U., Drago F. Effects of nicergoline on rabbit electroretinogram during recovery after ischaemia inlight and dark. Pharmacol. Res. 1997;36(5):363-368. DOI: 10.1006/phrs.1997.0240

44. Tanaka M., Yoshida T., Okamoto K. et al. Antioxidant prop- erties of nicergoline; inhibition of brain auto-oxidation and super-oxide production of neutrophils in rats. Neurosci. Lett. 1998;248(1):68-72. DOI: http://dx.DOI.org/10.1016/S0304-3940(98)00310-3

45. Saletu B., Griinberger J., Linzmayer L. et al. Brain protection of nicergoline against hypoxia: EEG brain mapping and psy- chometry. J. Neural. Transm. 1990;2(4):305-325. DOI: 10.1007/BF02252925

46. Fukushima I., Tagami K., Tomita S. et al. Effect oflong-term nicergoline administration on reology in elderly patients in the chronic stage of cerebral infarction. Kyorin. Igakkai. Zasshi. 2000;31(1):68-69

47. Li X.F., Hu C.L. Effect of nicergoline on cognition function of patients with cerebral infarction. Chin. J. Clin. Rehabil. 2005;9(9):186-187

48. Lliff L.D., Du Boulay G.H., Marshall J. et al. Effect of nicergoline on cerebral blood flow. J. Neurol. Neurosurg. Psychiatry. 1977;40(8):746-747. DOI: 10.1136/jnnp.40.8.746

49. Elwan O., Helmy A.A., Tamawy M.E. et al. Ergoloids and ischemic strokes; efficacy and mechanism of action. J. Int. Med. Res. 1995;23(3):154-166

50. Zylberman M.R., Fontana M., Dolce G. Effects of nicergoline onlearning, mood and behavior in hemiplegic patients un- dergoing rehabilitation. In: Kugler J., Agnoli A., editors. Ergot alkaloids and aging brain: an update on nicergoline. Amsterdam: Excerpta Medica, 1988:57-63

51. Novellini R., Battaglia A., Pamparana F. Rehabilitation training and drug treatment in after stroke patients: a comparison between nicergoline and piracetam [abstract]. XIV World Congress of Neurology; 1989:7-22

52. New Delhi. Kohashi N., Sakatani T., Kumon Y. et al. Quality of Life (QoL) of elderly cerebrovascular disorder patients treat- ed with a combination of rehabilitation training and nic- ergoline [abstract]. J. Hyogo. Med. Assoc. 1997;39(3):136

53. Kamizaki Y. Sermion® (nicergoline) therapy for sleeplessness associated with cerebrovascular disease. Pharma Medica. 2004;22(3):169-175

54. Katsumata T., Katayama Y. Treatment by medicine which improves cerebral circulation and metabolism. Nippon. Rinsho. 2006;64(8):81-84

55. Iwakuma H., Suenaga R., Hachimine K. et al. The significance of continuous administration of drugs, which improve cerebral circulation and metabolism, in the chronic stage of cerebral infarction and the usefulness of nicergoline for chronic-stage cerebral infarction. Pharma Medica. 2001;19(8):179-188

56. Корсунская Л.Л, Микляев А.А. Анализ эффективности комплексного профилактического воздействия ницерголина на функциональные показатели деятельности головного мозга у лиц пожилого возраста. Крымский терапевтический журнал. 2006;1:86-94

57. Nicergolin (Sermion). A Product Monograph. ADIS International. Milano. 1996:56

58. Логановский К.Н., Юрьев К.Л., Сермион. Актуальные вопросы применения в клинической практике. Украинский мед. Часопсис. 2005;1(45):49-57

59. Fioravanti M., Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst. Rev. 2001:4. DOI: 10.1002/14651858.CD003159

60. Battaglia A., Bruni G., Ardia A. et al. Nicergoline in mild to moderate dementia: a multicenter, double-blind, place- bo-controlled study. J. Am. Geriatr. Soc. 1989;37(4):295-302. DOI: 10.1111/j.1532-5415.1989.tb05494.x

61. Nappi G., Bono G., Merlo P. et al. Long-term nicergoline treatment of mild to moderate senile dementia: results of a multi-centre, double-blind, placebocontrolled study. Clin. Drug Invest. 1997;13(6):308-316. DOI: 10.2165/00044011-199713060-00003

62. Saletu B., Paulus E., Linzmayer L. et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology. 1995;117(4):385-395. DOI: 10.1007/BF02246209

63. Schneider F., Popa R., Mihalas G. et al. Superiority of antagonistic-stress composition versus nicergoline in gerontopsychiatry. Ann. N. Y. Acad. Sci. 1994;717:332-342. DOI: 10.1111/j.1749-6632.1994.tb12102.x

64. Herrmann W.M., Stephan K., Gaede K. et al. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement. Geriatr. Cogn. Disord. 1997;8(1):9-17. DOI:10.1159/000106595

65. Nicergoline Cooperative Study Group. A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Curr. Ther. Res. 1990;48(4):597-612

66. Crook T.H. Nicergoline in the treatment of probable Alzheim- er’s disease: preliminary results of a double-blind, rand- omized, placebo-controlled study. Neurol. Sci. 1997;1(12):18. DOI: http://dx.DOI.org/10.1016/S0022-510X(97)84910-6

67. Winblad B., Bonura M.L., Rossini B.M. et al. Nicergoline in the treatment of mild-to-moderate Alzheimer’s disease: a Euro- pean multicentre trial. Clin. Drug Invest. 2001;21(9):621-632. DOI: 10.2165/00044011-200121090-00004

68. Boulu P. Effets du Sermion® sur les troubles amnesiques et les functions de la vie de relation. Tempo medical. 1990;397:24-27

69. Zappoli R., Arnetoli G., Paganini M. et al. Topographic bitmapped event-related neurocognitive potentials and clinical status in patients with primary presenile mental decline chronically treated with nicergoline. Curr. Ther. Res. 1991;49 (6):1078-1097

70. Saletu B., Anderer P., Scmlitseh H.V. Relations between symptomatology and brain function in dementias: dou- ble-blind, placebo-controlled, clinical and EEG/ERP map- ping studies with nicergoline. Dement. Geriatr. Cogn. Dis- ord. 1997;8(1):12-21. DOI:10.1159/000106666

71. Arrigo A., Moglia A., Borsotti L. et al. A double-blind, placebo controlled, crossover trial with nicergoline in patients with senile dementia. Int. J. Clin. Pharmacol. Res. 1982;(4):33-41

72. Iwanami A., Fujishima T., Iritani S. et al. Effects of nic- ergoline on the P300 component of event-related poten- tials in demented patients. Neurol. Psychiatry Brain Res. 1993;1:232-234

73. Kurosu S., Mori Y., Kobayashi N. et al. Relationship of ERP to intellectual function and cerebral blood flow following Sermion® (nicergoline) treatment in patients with cere- brovascular dementia. Pharma Medica. 2002;20(9):2316

74. Hadjiev D.I., Yancheva S.T., Raychev I.R. et al. Clinical trial on the efficacy of nicergoline in patients with chronic cerebrovascular disorders. New Trends Clin. Neuropharmacol. 1993;VII(4):173-176

75. Sakamoto S., Katayama Y. Cerebral circulation- and metabolism-ameliorating drug (Sermion) [abstract]. J. Adult Dis. 2005;35(1):94

76. Nishiyama Y., Komaba Y., Mizumura S., et al. Antidepressive effect of nicergoline on patients with mild post-stroke depression. J Cereb Blood Flow Metab. 2005; 17: 11-16

77. Watanabe A., Ikejiri Y., Ikejiri Y. Nicergoline augmentation treatment of late onset depression. Psychogeriatrics. 2004;3(3):115-118. DOI: 10.1111/j.1479-8301.2003.00025.x

78. Martucci N., Borromei A., Costa P. et al. Nicergoline in Par- kinson’s disease: a multicentre double-blind placebo con- trolled study [abstract]. XIV World Congress of Neurology. New Delhi. 1989:7-22

79. Fariello R.G. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Funct. Neurol. 1997;12(3-4):221-225

80. Bes A., Orgogozo J.M., Poncet M. et al. A 24-monlh, double- blind, placebocontrolled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur. J. Neurol. 1999;6(3):313-322. DOI: 10.1046/j.1468-1331.1999.630313.x

81. Felisati G., Pignataro O., Di Girolamo A. et al. Nicergoline in the treatment of dizziness in elderly patients: a review. Arch. Gerontol. Geriatr. 2004;9:163-170. DOI: http://dx.DOI.org/10.1016/j.archger.2004.04.023

82. Rampello L., Drago F. Nicergoline facilitates vestibular compensation in aged male rats with unilateral labyrinthectomy. Neurosci. Lett. 1999;267(2):93-96. DOI: http://dx.DOI.org/10.1016/S0304-3940(99)00328-6

83. Giardino L., Zanni M., Fernandez M. et al. Plasticity of GABA(a) system during ageing: focus on vestibular com- pensation and possible pharmacological intervention. Brain Res. 2002;929(1):76-86. DOI: http://dx.DOI.org/10.1016/S0006-8993(01)03381-9

84. Felisati G., Battaglia A., Papini M.G. et al. Nicergoline in balance alterations in adult and elderly patients: a dou- ble-blind, placebo-controlled study. Clin. Drug Invest. 2002;22(11):731-740

85. Schonenberger F. Clinical study on nicergoline in peripheral arteriopathies. Farmaco Prat. 1976;31(11):561-567

86. Hasslinger C. Long-term study with nicergoline in ophfhal- mological practice. In: Hedrick H, editor. Proof of thera- peutical effectiveness of nootropic and vasoactive drugs: advances in clinical and experimental nicergoline research. New York: Springer-Verlag. 1986:195-202. DOI: 10.1007/978-3-642-70786-5_16

87. Parisi V., Colacino G., Milazzo G. et al. Effects of nicergoline on the retinal and cortical electrophysiological responses in glaucoma patients: a preliminary open study. Pharmacol. Res. 1999;40(3):249-255. DOI:10.1006/phrs.1999.0507

88. Tocchetti P., Strolin Benedetti M., Bani M. et al. Absorption and disposition of 14C-nicergoIine in healthy volunteers. Pharmacol. Res. 1997;35(3):224-225

89. Robert L., Migne J., Santonja R. et al. Plasma binding of an a-blocking agent, nicergoline: affinity for serum albumin and native and modified alpha1-acid glycoprotein. Int. J. Clin. Pharmacol. Ther. Toxicol. 1983;21(6):271-276


Для цитирования:


Пономарева Е.В. Применение ницерголина в геронтологической практике. Психиатрия. 2016;(71):106-120.

For citation:


. . Psychiatry. 2016;(71):106-120. (In Russ.)

Просмотров: 50


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1683-8319 (Print)
ISSN 2618-6667 (Online)